Current status of therapy for breast cancer worldwide and in Japan

doi:10.5306/wjco.v2.i2.125

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 2, Issue 2

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6901)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-14) series, Tables (1-3) series.

Item

Count

PDF

599

HTML

5830

Figures (1-14)

232

Tables (1-3)

240

Sum=6901

Feb 10, 2011 (publication date) through Dec 28, 2024

Times Cited of This Article

Times Cited (9)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Clin Oncol. Feb 10, 2011; 2(2): 125-134
Published online Feb 10, 2011. doi: 10.5306/wjco.v2.i2.125

Table 2 Molecule targeted therapeutic drugs

Target	Drug name
HER2	Trastuzumab
HER1/2	Lapatinib
HER2 (dimerization domain) (Pertuzumab inhibits the dimerization of the HER2 with other HER family receptors)	Pertuzumab
HER1/2/4	Neratinib
VEGF	Bevacizumab
Multi target (VEGFR, PDGFR etc)	Axitinib, sunitinib, pazopanib

HER: Human epidermal growth factor receptor; VEGF: Vascular endothelial cell growth factor; VEGFR: VEGF receptor; PDGFR: Platelet-derived growth factor receptor.

Citation: Park Y, Kitahara T, Takagi R, Kato R. Current status of therapy for breast cancer worldwide and in Japan. World J Clin Oncol 2011; 2(2): 125-134
URL: https://www.wjgnet.com/2218-4333/full/v2/i2/125.htm
DOI: https://dx.doi.org/10.5306/wjco.v2.i2.125